Expression of Sodium-glucose Co-transporter 2 in Human Heart

Expression of Sodium Glucose Co-transporter2 in Myocardium From Patients With Aortic Valve Stenosis and With/Without Diastolic Heart Failure

The aim of the study is to evaluate the expression of Sodium Glucose Co-transporter 2 (SGLT2) in myocardium from patients with aortic stenosis. 2 groups of patients will be defined: Group A with diastolic heart failure and Group B without heart failure. The expression of SGLT2 will be measured on small myocardium specimens harvested during aortic valve replacement operation. This study should allow us to better understand the effect of glifozines in human heart failure.

Inclusion Criteria:

• adults over 18 years-old
• Patient with surgical aortic valve stenosis, with or without heart failure, in two equal-sized groups (40 subjects in each group)
• Subjects affiliated with a social security health insurance plan
• Subject able to understand the objectives and risks of the research and to give dated and signed informed consent

Exclusion Criteria:

• Infective endocarditis in aortic stenosis
• Severe coronary pathology associated with aortic stenosis
• Impossible to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...)
• Subject under legal protection
• Subject under guardianship or curatorship
• Pregnancy and/or breastfeeding